Although p53 plays a crucial role in limiting the expansion of the CSC pool in breast [6], p53 restabilization in mammary tumours has had a limited therapeutic efficacy, due to the low frequency of tumours with WT p53 and the genetic pressure towards p53 loss/silencing in human cancer. The gene discussed is TP53; the disease is neoplasm.